Complexia and Health Expedience Executive Summary
Health Expedience is honored to announce its new pharmaceutical product – Complexia! Teaming with Aruba, Health Expedience was awarded the sole distribution contract for this unique, life-saving treatment. Complexia is hailed as a breakthrough in breast cancer treatment as it has been shown to reduce the recurrent of breast cancer during and after treatment. Using its on demand shipping process, Health Expedience will rush vital prescription medication direct to the patient. From there, Health Expedience will assist patient’s by working direct with prescribing oncologists to provide in-depth data and compassionate patient care. Aruba is also team with Health Expedience to facilitate in ongoing data collection to ensure product maximization and efficacy.
Complexia was recently approved by the Federal Drug Administration for use in the treatment of breast cancer. During clinical trials it was found that Complexia reduced the recurrence of breast cancer during and after treatment from 11 percent to 6 percent recurrence rate in a two-year period. There is great excitement among oncologists and patients and Health Expedience plans to build upon that excitement by hitting the ground running. The sales team, using its extensive relationship with oncologists, will continue to build product awareness and educate the public regarding Complexia benefits.
Product benefits will be realized quickly by patients as well, using Health Expedience’s On-Demand Shipping process; a unique and solid strategy that bi-passes traditional pharmacy distribution methods and streamlines shipment from warehouse to patient. With an expedited turn-around timeframe of 96-hours from the moment a prescribing oncologist enters the prescription into the eRx system, patients will receive their prescription in the comfort of their home. Customer service representatives will be readily available to assist individuals with shipping concerns and...